Clinical

Viridian Drug Successfully Meets Study Objectives as Treatment for Thyroid Eye Disease

Viridian announced that veligrotug, its potential thyroid eye disease (TED) drug, recorded impressive results in managing TED during a late-phase trial. The increase...

Relay Wins Early on Breast Cancer, Arranges Crucial Trial Against Truqap from AstraZeneca

Relay Therapeutics released interim Phase I/II data showing that RLY-2608, its investigational PI3Kα inhibitor, demonstrated “clinically meaningful” progression-free survival (PFS) in patients with specific...

Tern’s oral GLP-1 achieves 5% weight reduction within one month at the highest dose

Terns Pharmaceuticals’ decision to move away from the liver disease field may turn out to be beneficial since early phase 1 data suggests that...

GSK’s Asthma Drug Meets Primary Endpoint in Phase 3 Trial

After successfully completing two trials, SWIFT-1 and SWIFT-2, for its long-acting asthma drug depemokimab, GSK has now shared results for its Phase 3 trial....

Phase 2/3 of Athira Trial for Alzheimer’s Fails

Athira Pharma’s Phase 2/3 Alzheimer’s disease trial has ended in failure. The trial revealed that fosgonimeton performed no better than a placebo for the...

Sanofi’s Tolebrutinib faces defeat in 2 out of 3 phase 3 MS trials

Sanofi has announced that tolebrutinib, a BTK inhibitor, failed in two out of three Phase 3 trials. Tolebrutinib was being evaluated across two forms...

Novo Nordisk Says Goodbye to GLP-1/GIP MASH Prospect

Novo Nordisk has decided to discontinue the development of a medication candidate that it had highlighted earlier this year as an intriguing component of...

Agios Fails to Reach Primary Objective in Pediatric Study

In spite of the fact that it failed to meet the primary goal in a pediatric research, Agios has stated that it is continuing...

Latest news

Gilead and AI Drug Discovery Company Genesis Sign $35 Million Partnership

Genesis Therapeutics’ AI drug discovery platform, GEMS, has gained popularity and now attracted the attention of Gilead Sciences with...

Brightflow SAS Nabs $18M For Heart Failure Solution

Brightflow SAS, a privately owned company at the forefront in the area of long-term percutaneous mechanical circulatory assistance for...

Viridian Drug Successfully Meets Study Objectives as Treatment for Thyroid Eye Disease

Viridian announced that veligrotug, its potential thyroid eye disease (TED) drug, recorded impressive results in managing TED during...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you

Regeneron to conduct confirmatory trials for odronextamab for FDA approval

With Regeneron’s desire to move its blood cancer medicine...